Q-omics provides the consensus-scored FAM200A profile across patient tissues and cancer cell-line models. FAM200A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, FAM200A is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, FAM200A RNA expression shows 20,499 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, HNSC, and ACC as cancer lineages where FAM200A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM200A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM200A survival associations across molecular data types. FAM200A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM200A RNA expression–survival associations across cancer types. High FAM200A expression shows unfavorable associations in CESC, KICH, LIHC and STAD, but favorable associations in BRCA and KIRC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for FAM200A RNA expression.
This table summarizes FAM200A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM200A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM200A shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, BLCA, LUAD and BRCA. The HNSC box plot shows higher FAM200A RNA expression in tumor versus normal tissue (log2 FC = +0.841, t-test p < 0.001).
This table shows molecular features associated with FAM200A in patient tissues and cancer cell lines. In patient samples, FAM200A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM200A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
